These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 3761308)
1. Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics. Rollema H; Mastebroek D; Wikström H; Svensson K; Carlsson A; Sundell S J Med Chem; 1986 Oct; 29(10):1889-95. PubMed ID: 3761308 [TBL] [Abstract][Full Text] [Related]
2. In-vitro and in-vivo metabolism of the presynaptic dopamine agonist 3-PPP to a catecholic analogue in rats. Rollema H; Mastebroek D; Wikström H; Horn AS J Pharm Pharmacol; 1985 May; 37(5):314-9. PubMed ID: 2862239 [TBL] [Abstract][Full Text] [Related]
3. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system. Hjorth S Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921 [TBL] [Abstract][Full Text] [Related]
4. Relationship between brain levels of 3-(3-hydroxyphenyl)-N-n-propylpiperidine HCl enantiomers and effects on locomotor activity in rats. Lundström J; Lindgren JE; Ahlenius S; Hillegaart V J Pharmacol Exp Ther; 1992 Jul; 262(1):41-7. PubMed ID: 1352554 [TBL] [Abstract][Full Text] [Related]
6. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites. Koch SW; Koe BK; Bacopoulos NG Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267 [TBL] [Abstract][Full Text] [Related]
7. Resolved 3-(3-hydroxyphenyl)-N-n-propylpiperidine and its analogues: central dopamine receptor activity. Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson AM; Thorberg SO; Nilsson JL; Svensson K; Hjorth S J Med Chem; 1984 Aug; 27(8):1030-6. PubMed ID: 6086923 [TBL] [Abstract][Full Text] [Related]
8. N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors. Wikström H; Andersson B; Elebring T; Svensson K; Carlsson A; Largent B J Med Chem; 1987 Dec; 30(12):2169-74. PubMed ID: 2824773 [TBL] [Abstract][Full Text] [Related]
9. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751 [TBL] [Abstract][Full Text] [Related]
10. Lack of effect of intranigral administration of a dopamine analogue, (+/-)-3-(3-hydroxyphenyl)-N,n-propylpiperidine [(+/-)-3-PPP], on nigrostriatal dopamine neurones. Kelly E; Jenner P; Marsden CD Neurosci Lett; 1985 May; 56(1):57-62. PubMed ID: 4011049 [TBL] [Abstract][Full Text] [Related]
11. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers. Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247 [TBL] [Abstract][Full Text] [Related]
12. Behavioral and biochemical effects of subchronic treatment with (-)3-(3-hydroxyphenyl)-N-n-propylpiperidine in the rat: dopamine receptor sensitivity and tolerance. Ahlenius S; Hillegaart V; Magnusson O; Lundström J J Neural Transm; 1984; 60(2):103-13. PubMed ID: 6491654 [TBL] [Abstract][Full Text] [Related]
13. Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model. Liljefors T; Bøgesø KP; Hyttel J; Wikström H; Svensson K; Carlsson A J Med Chem; 1990 Mar; 33(3):1015-22. PubMed ID: 1968512 [TBL] [Abstract][Full Text] [Related]
15. Sexually differentiated actions of 3-PPP enantiomers on prolactin secretion. Carlsson M; Eriksson E; Nilsson C; Carlsson A Neuropharmacology; 1986 Aug; 25(8):951-4. PubMed ID: 3774120 [TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro. Mulder AH; Draper R; Sminia P; Schoffelmeer AN; Stoof JC Eur J Pharmacol; 1985 Jan; 107(3):291-7. PubMed ID: 3979429 [TBL] [Abstract][Full Text] [Related]
17. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. Eriksson E; Modigh K; Carlsson A; Wikström H Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196 [TBL] [Abstract][Full Text] [Related]
18. Effects of the enantiomers of 3-PPP on DA1 and DA2 dopamine receptors in the dog. Kohli JD; Glock D; Goldberg LI Eur J Pharmacol; 1985 Aug; 114(3):305-10. PubMed ID: 4065203 [TBL] [Abstract][Full Text] [Related]